Definitive Contract W15QKN20C0048

Glaxosmithkline, LLC, doing business as Glaxosmithkline, has been awarded a definitive contract by the Department of the Army to provide GLAXOSMITHKLINE ADJUVANT AS03. Valued at approximately $335.6 million, this firm fixed price contract runs from July 30, 2020 through December 30, 2022 and will be performed in Research Triangle Park, North Carolina. Under the contract, Glaxosmithkline will deliver its GLAXOSMITHKLINE ADJUVANT AS03 product to the Department of the Army in support of the agency's medical research and vaccine development programs. No major subcontractors or set aside designations were indicated.